{"organizations": [], "uuid": "e75aeee6e6c589edddf73d90a52614deb66ca545", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-menlo-therapeutics-announces-resul/brief-menlo-therapeutics-announces-results-from-phase-2-trial-of-serlopitant-for-pruritus-associated-with-atopic-dermatitis-idUSASC09V73", "country": "US", "domain_rank": 408, "title": "BRIEF-Menlo Therapeutics Announces Results From Phase 2 Trial Of Serlopitant For Pruritus Associated With Atopic Dermatitis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T08:23:00.000+03:00", "replies_count": 0, "uuid": "e75aeee6e6c589edddf73d90a52614deb66ca545"}, "author": "", "url": "https://www.reuters.com/article/brief-menlo-therapeutics-announces-resul/brief-menlo-therapeutics-announces-results-from-phase-2-trial-of-serlopitant-for-pruritus-associated-with-atopic-dermatitis-idUSASC09V73", "ord_in_thread": 0, "title": "BRIEF-Menlo Therapeutics Announces Results From Phase 2 Trial Of Serlopitant For Pruritus Associated With Atopic Dermatitis", "locations": [], "entities": {"persons": [{"name": "pha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "menlo therapeutics inc", "sentiment": "none"}, {"name": "pruritus associated with atopic dermatitis reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - Menlo Therapeutics Inc:\n* MENLO THERAPEUTICS ANNOUNCES RESULTS FROM A PHASE 2 TRIAL OF SERLOPITANT FOR PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS\n* ‍STUDY DID NOT MEET ITS PRIMARY OR KEY SECONDARY EFFICACY ENDPOINTS\n* ‍SERLOPITANT WAS WELL-TOLERATED IN THIS STUDY​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-09T08:23:00.000+03:00", "crawled": "2018-04-09T08:42:03.001+03:00", "highlightTitle": ""}